- Home
- LPRO vs UNCY Comparison
LPRO vs UNCY Comparison
Compare LPRO & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPRO | UNCY |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.4M | 145.3M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LPRO | UNCY |
|---|---|---|
| Price | $1.21 | $6.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $2.46 | ★ $44.50 |
| AVG Volume (30 Days) | ★ 560.5K | 455.4K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 96.46 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | $10.12 | N/A |
| Revenue Next Year | $17.80 | $401.76 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.70 | $0.45 |
| 52 Week High | $2.70 | $7.57 |
Technical Indicators
Market Signals| Indicator | LPRO | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 38.62 | 53.93 |
| Support Level | N/A | $6.48 |
| Resistance Level | $1.96 | $7.36 |
| Average True Range (ATR) | 0.10 | 0.35 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 6.74 | 63.44 |
Price Performance
Historical ComparisonAbout LPRO Open Lending Corporation
Open Lending Corp is a provider of lending enablement and risk analytics to credit unions, regional banks, finance companies and the captive finance companies of automakers (OEM captive finance companies). Through its flagship product, LPP, its customers, collectively referred to herein as automotive lenders or lenders, make automotive consumer loans to underserved near-prime and non-prime borrowers by harnessing its risk-based interest rate pricing models, powered by its proprietary data and real-time underwriting of automotive loan default insurance coverage from insurers.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.